BB Biotech (BION) Stock Overview

An equity fund launched and managed by Bellevue Asset Management AG. More details

BION fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	3/6
Financial Health	6/6
Dividends	4/6

BION Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW488,799 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

488,799 investors already sharing narratives

View all narratives

BB Biotech AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for BB Biotech
Historical stock prices
Current Share Price	CHF 53.70
52 Week High	CHF 56.20
52 Week Low	CHF 44.95
Beta	0.65
1 Month Change	10.04%
3 Month Change	5.92%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	9.59%

Recent updates

Shareholder Returns

	BION	AT Capital Markets	AT Market
7D	-1.6%	1.0%	-1.5%
1Y	n/a	5.8%	30.7%

Return vs Industry: Insufficient data to determine how BION performed against the Austrian Capital Markets industry.

Return vs Market: Insufficient data to determine how BION performed against the Austrian Market.

Price Volatility

Is BION's price volatile compared to industry and market?
BION volatility
BION Average Weekly Movement	3.5%
Capital Markets Industry Average Movement	3.9%
Market Average Movement	4.2%
10% most volatile stocks in AT Market	6.3%
10% least volatile stocks in AT Market	2.5%

Stable Share Price: BION has not had significant price volatility in the past 3 months compared to the Austrian market.

Volatility Over Time: Insufficient data to determine BION's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	10	n/a	www.bbbiotech.ch/en/bb-biotech/

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.

BB Biotech AG Fundamentals Summary

How do BB Biotech's earnings and revenue compare to its market cap?
BION fundamental statistics
Market cap	€2.96b
Earnings (TTM)	€863.85m
Revenue (TTM)	€668.04m

3.4x

P/E Ratio

4.4x

P/S Ratio

Is BION overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BION income statement (TTM)
Revenue	CHF 616.88m
Cost of Revenue	CHF 0
Gross Profit	CHF 616.88m
Other Expenses	-CHF 180.81m
Earnings	CHF 797.69m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 24, 2026

Earnings per share (EPS)	14.46
Gross Margin	100.00%
Net Profit Margin	129.31%
Debt/Equity Ratio	0%

How did BION perform over the long term?

See historical performance and comparison

Dividends

4.5%

Current Dividend Yield

15%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/19 09:30
End of Day Share Price	2026/07/17 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BB Biotech AG is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Rene Rückert	Baader Helvea Equity Research
Thomas Meyer	Baader Helvea Equity Research
Falko Friedrichs	Deutsche Bank

BB Biotech AGWBAG:BION Stock Report